Matthew J. Ahearne - Concepedia

Author

Matthew J. Ahearne

University of Leicester ORCID

Also Known As

Ahearne, M, Ahearne, M., M. Ahearne, Matthew Ahearne, Matthew J A'Hearne, Matthew J Ahearne, Matthew J. Ahearne

Publications

957

Citations

H-Index

Concepts

All Affiliations

University of Leicester University Hospitals of Leicester NHS Trust University College London Nottingham University Hospitals NHS Trust University Hospital Southampton NHS Foundation Trust

About

Matthew J. Ahearne is an author at University of Leicester specializing in medicine, immunotherapy, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	229
2	Immunology	5	5	217
3	Cell Biology	2	2	41
4	Medical Laboratory Science	1	1	26
5	Molecular Medicine	1	1	19

Matthew J. Ahearne

Publications

682

Citations

H-Index

Page 1

	Year	Citations
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study Sean H. Lim, Beth Stuart, Débora Joseph‐Pietras, Nature Cancer	2022	87
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma Sean H. Lim, Nicola Campbell, Marina Johnson, The Lancet Haematology VaccinationVaccine DevelopmentImmunologySars-cov-2 VaccinationImmunotherapy	2021	84
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients Nicole Wong Doo, Carole Soussain, Sylvain Choquet, UCL Discovery (University College London)	2022	76
Enhancement of <scp>CD</scp>154/<scp>IL</scp>4 proliferation by the <scp>T</scp> follicular helper (<scp>T</scp>fh) cytokine, <scp>IL</scp>21 and increased numbers of circulating cells resembling <scp>T</scp>fh cells in chronic lymphocytic leukaemia Matthew J. Ahearne, Shaun Willimott, Lucia Piñon, British Journal of Haematology	2013	69
Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma Matthew J. Ahearne, Kaljit Bhuller, Roger Hew, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin Tumor BiologyLymphoid NeoplasiaImmunologyPathologyAdult T-cell Leukemia-lymphoma	2014	66
Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis Nicolás Martínez‐Calle, Sarah Hartley, Matthew J. Ahearne, British Journal of Haematology	2018	56
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery Matthew R. Wilson, Toby A. Eyre, Nicolás Martínez‐Calle, Blood Advances	2020	53
Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia Shaun Willimott, Daniel Beck, Matthew J. Ahearne, Clinical Cancer Research	2013	36
Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma Sami Mamand, Rebecca L. Allchin, Matthew J. Ahearne, Scientific Reports	2018	36
Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline Christopher P. Fox, Matthew J. Ahearne, Ruth Pettengell, British Journal of Haematology Natural Killer‐cell LymphomasBritish JournalMature T‐Lymphoid NeoplasiaMedicine	2021	26

Page 1